Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer.

Parikh RB, Adamson BJS, Khozin S, Galsky MD, Baxi SS, Cohen A, Mamtani R.

JAMA. 2019 Sep 24;322(12):1209-1211. doi: 10.1001/jama.2019.10650. No abstract available.

2.

Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R.

Eur Urol. 2019 Oct;76(4):524-532. doi: 10.1016/j.eururo.2019.07.032. Epub 2019 Jul 28.

PMID:
31362898
3.

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice.

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson BJS, Gross CP, Meropol NJ, Mamtani R.

Oncologist. 2019 Jun;24(6):e397-e399. doi: 10.1634/theoncologist.2019-0039. Epub 2019 Apr 3.

4.

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC).

El-Deiry WS, Winer A, Slifker M, Taylor S, Adamson BJS, Meropol NJ, Ross EA.

Front Oncol. 2019 Mar 14;9:142. doi: 10.3389/fonc.2019.00142. eCollection 2019.

5.

Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.

Selinger C, Bershteyn A, Dimitrov DT, Adamson BJS, Revill P, Hallett TB, Phillips AN, Bekker LG, Rees H, Gray G.

Vaccine. 2019 Apr 10;37(16):2258-2267. doi: 10.1016/j.vaccine.2019.02.073. Epub 2019 Mar 16.

6.

Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling study.

de Montigny S, Adamson BJS, M√Ęsse BR, Garrison LP Jr, Kublin JG, Gilbert PB, Dimitrov DT.

Sci Rep. 2018 Apr 17;8(1):6066. doi: 10.1038/s41598-018-24268-4.

7.

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Adamson BJS, Carlson JJ, Kublin JG, Garrison LP.

Vaccines (Basel). 2017 May 24;5(2). pii: E13. doi: 10.3390/vaccines5020013.

8.

A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines.

Adamson BJ, Fuchs JD, Sopher CJ, Flood DM, Johnson RP, Haynes BF, Kublin JG; NIAID HIV Vaccine Trials Network.

Clin Transl Sci. 2015 Apr;8(2):166-8. doi: 10.1111/cts.12249. Epub 2014 Dec 30.

Supplemental Content

Loading ...
Support Center